Stockreport

Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock

Windtree Therapeutics, Inc.  (WINT) 
Last windtree therapeutics, inc. earnings: 8/21 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: windtreetx.investorroom.com
PDF WARRINGTON, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on adva [Read more]